Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Julia M. Greene"'
Autor:
Tommy A. Brown, Kevin Byrd, Timothy J. Vreeland, Guy T. Clifton, Doreen O. Jackson, Diane F. Hale, Garth S. Herbert, John W. Myers, Julia M. Greene, John S. Berry, Jonathan Martin, John C. Elkas, Thomas P. Conrads, Kathleen M. Darcy, Chad A. Hamilton, George L. Maxwel, George E. Peoples
Publikováno v:
Cancer Medicine, Vol 8, Iss 10, Pp 4678-4687 (2019)
Abstract Background E39, an HLA‐A2‐restricted, immunogenic peptide derived from the folate‐binding protein (FBP), is overexpressed in multiple malignancies. We conducted a phase I/IIa trial of the E39 + GM‐CSF vaccine with booster inoculation
Externí odkaz:
https://doaj.org/article/f15fd5bad15e44cabf5f4b8e235a3c91
Autor:
Sathibalan Ponniah, Tommy A. Brown, Diane F. Hale, Constantin N. Baxevanis, N. F. Pistamaltzian, John W. Myers, Kaitlin M. Peace, Eleftheria A. Anastasopoulou, Doreen O. Jackson, Jennifer K. Litton, James L. Murray, Michael Papamichail, Nathan M. Shumway, James T. Symanowski, George E. Peoples, Alexandros Ardavanis, Elizabeth A. Mittendorf, Sonia A. Perez, Timothy J. Vreeland, Julia M. Greene, G. Travis Clifton
Publikováno v:
Breast Cancer Research and Treatment
Purpose AE37 and GP2 are HER2 derived peptide vaccines. AE37 primarily elicits a CD4+ response while GP2 elicits a CD8+ response against the HER2 antigen. These peptides were tested in a large randomized trial to assess their ability to prevent recur
Autor:
Timothy J. Vreeland, Chad A. Hamilton, John S. Berry, Kathleen M. Darcy, George E. Peoples, Garth S. Herbert, Kevin Byrd, Jonathan W. Martin, Tommy A. Brown, Julia M. Greene, Diane F. Hale, George L. Maxwel, Guy T. Clifton, John W. Myers, Doreen O. Jackson, John C. Elkas, Thomas P. Conrads
Publikováno v:
Cancer Medicine, Vol 8, Iss 10, Pp 4678-4687 (2019)
Cancer Medicine
Cancer Medicine
Background E39, an HLA‐A2‐restricted, immunogenic peptide derived from the folate‐binding protein (FBP), is overexpressed in multiple malignancies. We conducted a phase I/IIa trial of the E39 + GM‐CSF vaccine with booster inoculations of eith
Autor:
Thomas E. Wagner, George E. Peoples, Guy T. Clifton, Xianzhong Yu, Pauline Nichol, Mark O. Hardin, Diane F. Hale, Doreen O. Jackson, John S. Berry, Julia M. Greene, Garth S. Herbert, Timothy J. Vreeland, Sook Yin
Publikováno v:
Vaccine. 36:3247-3253
Introduction Tumor vaccines use various strategies to generate immune responses, commonly targeting generic tumor-associated antigens. The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is produced from DC loaded with autologous tumor
Autor:
Timothy J. Vreeland, Guy T. Clifton, Doreen O. Jackson, George E. Peoples, Pauline Nichols, Garth S. Herbert, John E Berry, Diane F. Hale, Mark O. Hardin, Julia M. Greene, Sook Yin, Xianzhong Yu, Thomas E. Wagner
Publikováno v:
Immunotherapy. 10:373-382
Aim: We developed a novel approach to efficiently deliver autologous tumor antigens to the cytoplasm of dendritic cells (DC) using yeast cell wall particles (YCWP). Materials and Methods: Loading of YCWP, leakage of protein from loaded YCWP and cytop
Autor:
Timothy J. Vreeland, A Toms, Julia M. Greene, Nuhad K. Ibrahim, Na Qiao, Doreen O. Jackson, EA Mittendorf, Guy T. Clifton, Kaitlin M. Peace, Diane F. Hale, George E. Peoples, Alfred F. Trappey, John S. Berry
Publikováno v:
Cancer Research. 77:P6-10
BACKGROUND FBP is overexpressed in 20-50% of breast(B) cancers(Ca) and roughly 90% of endometrial(E) and ovarian (Ov) Ca. E39 (FBP191-199, EIWTHSYKV)+GM-CSF is an HLA-A2 restricted FBP peptide vaccine, which has been shown to generate significant in
Autor:
George E. Peoples, Alfred F. Trappey, Guy T. Clifton, Julia M. Greene, D F Hale, Timothy J. Vreeland, Garth S. Herbert, John S. Berry, Doreen O. Jackson, Mark O. Hardin
Publikováno v:
Journal of Cancer
Introduction Peptide vaccines offer anti-tumor efficacy with very low toxicity. However, repeat stimulation with an immunogenic peptide leads to activation induced cell death (AICD), decreasing efficacy. We engineered variants of an immunogenic pepti
Autor:
Madeline Flores, Garth S. Herbert, Jonathan Martin, Diane F. Hale, Xianzhong Yu, George E. Peoples, Mark O. Hardin, Julia M. Greene, Doreen O. Jackson, Timothy J. Vreeland, Erika J Schneble, Thomas E. Wagner
Publikováno v:
Cancer Immunology, Immunotherapy. 65:383-392
Stage IV melanoma has high mortality, largely unaffected by traditional therapies. Immunotherapy including cytokine therapies and checkpoint inhibitors improves outcomes, but has significant toxicities. In this phase I/IIa trial, we investigated safe
Autor:
Timothy J. Vreeland, Julia M. Greene, Jennifer K. Litton, Michael Papamichail, Sonia A. Perez, Alexandros Ardavanis, Guy T. Clifton, Nathan M. Shumway, James L. Murray, Erika J Schneble, Diane F. Hale, George E. Peoples, EA Mittendorf, John S. Berry, Alfred F. Trappey
Publikováno v:
Cancer Research. 76:P2-11
Introduction: We are conducting a phase II clinical trial of the GP2+GM-CSF vaccine for the prevention of breast cancer recurrence in disease-free, node-positive or high-risk node negative patients (pts). GP2 is an HLA-A2+-restricted immunogenic pept
Autor:
George E. Peoples, Julia M. Greene, Jennifer K. Litton, Na Qiao, Elizabeth A. Mittendorf, Kaitlin M. Peace, Guy T. Clifton, Timothy J. Vreeland, John S. Berry, Gheath Alatrash, Diane F. Hale, Anne V. Philips, Doreen O. Jackson
In this randomized phase Ib trial, we tested combining the E39 peptide vaccine with a vaccine created from E39’, an attenuated version of E39. Patients with breast or ovarian cancer, who were disease-free after standard of care therapy, were enroll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0df5c2928021e21a4c44f640f5908100
https://europepmc.org/articles/PMC5988975/
https://europepmc.org/articles/PMC5988975/